The landscape of metabolic and cardiovascular health is being fundamentally reshaped by a class of drugs known as SGLT2 inhibitors. Originally developed for glycemic control in Type 2 Diabetes Mellitus (T2DM), the "gliflozin" trio—Empagliflozin, Dapagliflozin, and Canagliflozin Market has evolved into a multi-organ protective therapy. https://www.databridgemarketresearch.com/